Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1364342 | Bioorganic & Medicinal Chemistry Letters | 2008 | 7 Pages |
The synthesis and SAR for a series of diaminopyrimidines as PYK2 inhibitors are described. Using a combination of library and traditional medicinal chemistry techniques, a FAK-selective chemical series was transformed into compounds possessing good PYK2 potency and 10- to 20-fold selectivity against FAK. Subsequent studies found that the majority of the compounds were positive in a reactive metabolite assay, an indicator for potential toxicological liabilities. Based on the proposed mechanism for bioactivation, as well as a combination of structure-based drug design and traditional medicinal chemistry techniques, a follow-up series of PYK2 inhibitors was identified that maintained PYK2 potency, FAK selectivity and HLM stability, yet were negative in the RM assay.
Graphical abstractSynthesis and structure–activity relationships for a series of diaminopyrimidines as proline-rich tyrosine kinase (PYK2) inhibitors are described. Strategies for the elimination of reactive metabolite formation within this chemical series are also described.Figure optionsDownload full-size imageDownload as PowerPoint slide